Reported results
- Revenue was $150.7 million for the third quarter of 2026.
- Gross margin was 75% for the third quarter of 2026.
- Operating expenses were $129.0 million for the third quarter of 2026.
- Operating loss was $16.1 million for the third quarter of 2026.
- Net loss was $19.4 million for the third quarter of 2026.
- Cash and cash equivalents and marketable securities were $575.7 million as of September 30, 2026.
Guidance
- 10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $625 million to $635 million.
Price and volatility reaction
The stock moved +2.1% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +2.2 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 58.06 | 2026-11-05 |
| Close after release | 59.28 | 2026-11-06 |
| Realised move | +2.1% | close to close |
| 30d ATM IV change | +2.2 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
